NCT01117051 2021-06-11
OIC
Takeda
Phase 3 Terminated
Clinical Trials
9 trialsNCT01696643 2018-11-15
Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT01901302 2018-11-15
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT01901341 2018-11-15
The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT01395524 2017-02-23
A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation
AstraZeneca
Phase 3 Completed
NCT01323790 2015-06-02
Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
AstraZeneca
Phase 3 Completed
NCT01309841 2015-06-01
Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
AstraZeneca
Phase 3 Completed
NCT01384292 2015-06-01
Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain
AstraZeneca
Phase 3 Terminated
NCT01336205 2014-10-20
Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
AstraZeneca
Phase 3 Completed